Cabaletta Bio Reports Promising Advances in Autoimmune Disease Trials, Looks to Future Innovations
PHILADELPHIA, PA — Cabaletta Bio, Inc. (Nasdaq: CABA) this week unveiled promising updates on its clinical trials and financial standing for the first quarter ending March 31, 2024. The company’s …
Cabaletta Bio Reports Promising Advances in Autoimmune Disease Trials, Looks to Future Innovations Read More